Rocket Pharmaceuticals secures $150M credit facility

Rocket Pharmaceuticals secured a $150 million term loan from Hercules Capital, with a $35 million initial draw. The loan has a 2030 maturity, extendable to 2031, and includes interest-only periods tied to milestones. The company also issued warrants for up to 1.76 million shares at $2.99 to lenders. The funding aims to support its pipeline, including RP-A501 for Danon Disease, and operations.

Rocket Pharmaceuticals (RCKT) secured a $150M credit facility with Hercules Capital, with $35M received at closing. The facility includes additional tranches tied to milestones and approvals, with a 30-month interest-only period and 48-month maturity. The funds will support a Phase 2 Danon study and cardiovascular pipeline.

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.